Today’s genomic solutions. Tomorrow’s cancer breakthroughs.
Join us at ASCO 2019 to learn how Illumina genomic solutions are enabling comprehensive genomic profiling, including fusion detection, agnostic of fusion partner. With advancements in the understanding of the role of NTRK fusions in advanced solid tumors, and the potential for TKI inhibitors, it’s more important than ever to detect and characterize these rare fusion events. However, not all detection methods are equal. In fact, 60% of NTRK fusion partners can be missed by commercially available amplicon-based NTRK detection assays. Learn how Illumina NGS technology detects more fusions, including NTRK fusions. With genomic advancements comprehensive fusion detection, the possibilities are limitless.
Visit us at booth 24111 and at our events to learn more.
Industry Expert Theater presentation
Industry Expert Theater
Saturday, June 1
Title: Comprehensive NTRK fusion detection, agnostic of the fusion partner, for identification of rare genomic events: perspectives from an oncologist and pathologist
Phil Febbo, Oncologist and SVP, Chief Medical Officer, Illumina
Sue, Beruti, Pathologist and Senior Director, Illumina